Capricor Phase 3 HOPE-3 trial of CAP-1002 in DMD passes interim futility analysis; milestone payment triggered

CAPRICOR THERAPEUTICS, INC.

Positive interim futility analysis from DSMB; trial to continue as planned.
Triggers first milestone payment under U.S. agreement with Nippon Shinyaku.
HOPE-3 Cohort A enrollment complete; topline data expected Q4 2024.
Company plans to request FDA meeting in Q1 2024 for expedited approval pathways.
Cohort B enrollment initiated; ~102 subjects total across both cohorts.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.